โรคโคโรน่าไวรัส 2019 (COVID-19) กับงานบริการโลหิต
Keywords:
-Abstract
-
Downloads
References
Singhal T. A review of coronavirus disease-2019 (COVIC-19). Indian J Pediatr. 2020;87:281-6.
Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al. COVID-19 Outbreak: An Overview. Chemotherapy. 2019;64:215-23.
Wu YC, Chen CS, Chen YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83:217-20.
Li X, Geng M, Peng Y, Meng L, Lu Shemin. Molecular immune pathogenesis and diagnosis of COVID-19. Int J Pharm Anl. 2020;10:102-8.
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1-9.
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structure basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444-8.
Abdulamir AS, Hafidh RR. The possible immunological pathways for the variable immunopathogenesis of COCID-19 infections among healthy adults, elderly and childen. Electron J Gen Med. 2020;17:em202. doi: 10.29333/ejgm/7850.
Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et.al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202:415-24.
Du L, He Y, Zhou Y, Liu S, Zheng Bo-Jian, Jiang S. The spike protein of SARS-CoV- a target for vaccine and therapeutic development. Nature Reviews Microbiology. 2009;7:226-36.
Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et.al. Towards effective COVID-
vaccines: updates, perspective and challenges. Int J Mol Med. 2020;46:3-16.
Hung IFN, To KWK, Lee CK, Lee KL, Chan K, Yah WW, et.al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447-56.
Griensven JV, Edward T, Lamballerie XD, Semple MG, Gallian P, Baize S, et.al. Evaluation of convalescent plasma for ebola virus disease in Guinea. N Engl J Med. 2016;374:33-42.
Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, et.al. The Use of TKM-100802 and convalescent plasma in 2 patients with ebola virus disease in the United States. Clin Infect Dis. 2015;61:496-501.
Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et.al. Use of convalescent plasma theraphy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44-6.
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et.al. Deployment of covalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-65.
Duan K, Liu B, Li Cesheng, Zhang H, Yu T, Qu J, et.al. Effectiveness of covalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U.S.A. 2020;117:9490-6.
Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545-8.
Shanmugaraj B, Siriwattananon K, Wangkanont K and Phoolcharoen W. Perspective on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38:10-8.
Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34:75-80.
World Health Organization. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent
plasma. [cited 2020 July 10] [about 6p.] Available from: https//app s.who.int./iris/handle/10665/333182.
